AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 28646924
Drug: Household-level prophylaxis
RxNorm normalized name: peanut allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Household-level prophylaxis with single-dose ciprofloxacin
Trial: 28646924
Drug: Village-wide prophylaxis
RxNorm normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Village-wide prophylaxis with single-dose ciprofloxacin
Trial: 23351188
Drug: GM1 (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GM1 (100 mg once daily for 3 days)
Trial: 23351188
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no neuroprotective agents)
Trial: 20003436
Drug: Atorvastatin 40
RxNorm normalized name: atorvastatin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin 40 mg per os daily
Trial: 20003436
Drug: Subcutaneous interferon
RxNorm normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous interferon beta-1b every other day
Trial: 17261601
Drug: LT vaccine
RxNorm normalized name: hepatitis A adult vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LT vaccine patch (50 microg) administered on days 0 and 21
Trial: 17261601
Drug: Oral ETEC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral ETEC challenge (LT+ ST+ E2447A)
Trial: 17261601
Drug: Oral cholera
RxNorm normalized name: VIBRIO CHOLERAE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral cholera toxin B subunit-containing cholera vaccine
Trial: 15059332
Drug: Stenting followed
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Stenting followed by radiotherapy and/or chemotherapy (Group B, n = 26)
Trial: 15059332
Drug: Stenting followed
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Stenting followed by radiotherapy and/or chemotherapy (Group B)
Trial: 11224828
Drug: Oseltamivir 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oseltamivir 2 mg/kg/dose twice daily for 5 days
Trial: 8968633
Drug: Exposure therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exposure therapy with ritual prevention
Trial: 6776577
Drug: Combined alcohol
RxNorm normalized name: Alcohol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Combined alcohol + tobacco (4 cigarettes + 0.65 g/kg ethyl alcohol)
Trial: 22748849
Drug: Fibrin-based biological
RxNorm normalized name: Cytokine-based biologic agent IRX-2
DrugBank: IRX-2 (DB05643)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fibrin-based biological adhesive applied to the suture line
Trial: 10404769
Drug: E2 (2
RxNorm normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: E2 (2 mg micronised oestradiol daily)
Trial: 8803649
Drug: Fluvoxamine (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluvoxamine (up to 150 mg/day as a single bedtime dose)
Trial: 8803649
Drug: Imipramine (240
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imipramine (240 mg/day on a twice‐daily schedule)
Trial: 24668660
Drug: Rivaroxaban 20
RxNorm normalized name: rivaroxaban 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rivaroxaban 20 mg for normal/mildly impaired renal function
Trial: 24668660
Drug: Rivaroxaban 15
RxNorm normalized name: rivaroxaban 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rivaroxaban 15 mg for moderate renal impairment
Trial: 17989110
Drug: Pharmacogenetic-guided dosing
RxNorm normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacogenetic-guided dosing (wild-type patients)
Trial: 17989110
Drug: Standard dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dosing (wild-type patients)
Trial: 17989110
Drug: Pharmacogenetic-guided dosing
RxNorm normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacogenetic-guided dosing (multiple variant carriers)
Trial: 17989110
Drug: Standard dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dosing (multiple variant carriers)
Trial: 16301267
Drug: Continuous femoral
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous femoral nerve blockade (CFNB) with bupivacaine 0.2% (median infusion rate 9.3 mL/h)
Trial: 16301267
Drug: Continuous epidural
RxNorm normalized name: ACCU-BLOC PERIFIX CONTINUOUS EPIDURAL ANESTHESIA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous epidural analgesia (CEA) with ropivacaine 0.2% and fentanyl 4 microg/mL (median infusion rate 7.6 mL/h)
Trial: 391342
Drug: Trimipramine (tricyclic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimipramine (tricyclic antidepressant; mean dose 106 mg at night)
Trial: 391342
Drug: Monoamine oxidase
RxNorm normalized name: Monoamine oxidase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monoamine oxidase inhibitors (MAOIs; phenelzine mean dose 45 mg/day, isocarboxazid mean dose 32 mg/day)
Trial: 391342
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment (phenelzine plus trimipramine or isocarboxazid plus trimipramine)
Trial: 30282088
Drug: Tissue-level implants
RxNorm normalized name: allogeneic processed thymus tissue Drug Implant [Rethymic]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tissue-level implants restored by platform matching (control)
Trial: 30282088
Drug: Bone-level implants
RxNorm normalized name: bone meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bone-level implants restored by platform switching (test)
Trial: 16928616
Drug: Increased urinary
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increased urinary podocyte mRNA excretion
Trial: 14769712
Drug: Amiodarone, 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amiodarone, 200 mg/d
Trial: 14769712
Drug: Propafenone, 450
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propafenone, 450 mg/d
Trial: 11379374
Drug: Synthetic conjugated
RxNorm normalized name: synthetic conjugated estrogens, A
DrugBank: Synthetic Conjugated Estrogens, A (DB09317)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Synthetic conjugated estrogen tablets
Trial: 9135227
Drug: Alendronate (7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alendronate (7.5 mg dissolved in 250 ml saline solution)
Trial: 9135227
Drug: Placebo saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo saline infusions
Trial: 9135227
Drug: Alendronate (7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alendronate (7.5 mg/day for three days, open label)
Trial: 7955026
Drug: High-titre measles
RxNorm normalized name: MEASLES VIRUS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-titre measles vaccine (EZ-HT, SW-HT)
Trial: 3680601
Drug: Caffeine (64
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (64 mg) + Aspirin (800 mg)
Trial: 3680601
Drug: Caffeine (64
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (64 mg)
Trial: 3680601
Drug: Aspirin (800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (800 mg)
Trial: 28064163
Drug: Spironolactone 12.5-50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spironolactone 12.5-50 mg/day
Trial: 27917793
Drug: i.v. furosemide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.v. furosemide (200‐300 mg bid) and 3% hypotonic saline solution (HSS) (once or twice a day)
Trial: 27917793
Drug: oral furosemide
RxNorm normalized name: Furosemide
DrugBank: Furosemide (DB00695)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral furosemide tablets (360‐520 mg bid) and salt (2.5 g bid)
Trial: 27917793
Drug: repeated large‐volume‐paracentesis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: repeated large‐volume‐paracentesis (RLVP) with albumin infusion
Trial: 24873894
Drug: Soybean leaf
RxNorm normalized name: SOYBEAN
DrugBank: Soybean (DB10568)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soybean leaf extracts (SLE) 2 g per day
Trial: 24873894
Drug: Banaba extracts
RxNorm normalized name: banana extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Banaba extracts (BE) 300 mg per day
Trial: 24873894
Drug: Placebo (starch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (starch 2 g per day)
Trial: 15756156
Drug: Group 1:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group 1: midazolam (0.015‐0.030 mg/kg) and sufentanil (0.15‐0.20 microg/kg)
Trial: 15756156
Drug: Group 2:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group 2: midazolam (0.15‐0.2 mg/kg) and continuous remifentanil infusion 0.5‐1 microg/kg/min followed by 0.05 microg/kg/min
Trial: 7670590
Drug: Intracavernosal injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intracavernosal injection of prostaglandin E1 with RMRI penile clamp
Trial: 7670590
Drug: Intracavernosal injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intracavernosal injection of prostaglandin E1 without RMRI penile clamp
Trial: 31816191
Drug: 2 mL
RxNorm normalized name: ethanol 2 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mL of 1:100,000 epinephrine injected intranasally
Trial: 31816191
Drug: 2 mL
RxNorm normalized name: ethanol 2 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mL of 1:200,000 epinephrine injected intranasally
Trial: 31816191
Drug: Topical 1:1000
RxNorm normalized name: thimerosal topical 1:1000 topical spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 1:1000 epinephrine pledgets placed after injection of epinephrine
Trial: 23150678
Drug: Insulin infusion
RxNorm normalized name: iLet Insulin Infusion 10-Pack Kit Inset
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin infusion at 4, 8, and 40 mU/m2 · min during a three-stage hyperinsulinemic/euglycemic clamp after dietary control and overnight insulin infusion.
Trial: 21770925
Drug: USL255 (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: USL255 (200 mg) in fasted conditions
Trial: 21770925
Drug: USL255 (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: USL255 (200 mg) in fed conditions
Trial: 21770925
Drug: Topamax (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topamax (100 mg) administered 12 h apart
Trial: 19325515
Drug: Praziquantel (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Praziquantel (75 mg/kg/d for 1 day) with albendazole (15 mg/kg/d for 7 days)
Trial: 19325515
Drug: Albendazole (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albendazole (15 mg/kg/d for 7 days)
Trial: 17661565
Drug: Oral vitamin
RxNorm normalized name: vitamin A Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral vitamin D supplementation (control for infants)
Trial: 14974311
Drug: 90 ml
RxNorm normalized name: 190 ML Infugem 10 MG/ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 90 ml sodium phosphate with an additional 2.5 litres of fluid
Trial: 14974311
Drug: Combined PEG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined PEG solutions (PEG 4000 and PEG 3350)
Trial: 10771930
Drug: Regular transfusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular transfusion therapy
Trial: 30630184
Drug: Round window
RxNorm normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Round window niche drilling combined with daily intratympanic methylprednisolone for 7 times
Trial: 30630184
Drug: Daily intratympanic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily intratympanic methylprednisolone for 7 times
Trial: 23953030
Drug: Irinotecan 3-weekly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irinotecan 3-weekly 350 mg/m² (or 300 mg/m² if age >70 or performance status (PS)=2)
Trial: 23953030
Drug: Irinotecan 3-weekly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irinotecan 3-weekly 140 mg/m² (120 mg/m² if age >70 or PS=2) with ciclosporin 3 mg/kg t.d.s. for three days by mouth starting on the morning before irinotecan
Trial: 21050027
Drug: Nasal budesonide
RxNorm normalized name: budesonide Nasal Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal budesonide 100 μg, 1 puff per nostril twice a day
Trial: 15640636
Drug: Inhaled isoflurane
RxNorm normalized name: isoflurane Inhalation Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled isoflurane via the Anesthetic Conserving Device
Trial: 15640636
Drug: Intravenous midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous midazolam infusion
Trial: 11699174
Drug: 10% carbamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10% carbamide peroxide bleaching agent (Opalescence/Ultradent)
Trial: 9159691
Drug: Topical heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical heparin eyedrops
Trial: 30730938
Drug: Daily power
RxNorm normalized name: ZO SKIN HEALTH OSSENTIAL DAILY POWER DEFENSE ANTI-AGING FORMULA and OCLIPSE SUNSCREEN PLUS PRIMER BROAD SPECTRUM SPF 30 UVA/UVB PROTECTION KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily power posing practice
Trial: 23686706
Drug: Testosterone undecanoate
RxNorm normalized name: Testosterone Undecanoate
DrugBank: Testosterone undecanoate (DB13946)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone undecanoate (1,000 mg)
Trial: 21160218
Drug: Intramuscular lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intramuscular lidocaine 1.5 mg · kg(‐1) administered into the deltoid muscle 10 min before anaesthesia induction
Trial: 21160218
Drug: Intravenous lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous lidocaine 1.5 mg · kg(‐1), 2 min before anaesthesia induction
Trial: 21160218
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group received only propofol injection
Trial: 15726852
Drug: CTiP-fabricated frameworks
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CTiP-fabricated frameworks directly to Brånemark implants
Trial: 15726852
Drug: Brånemark implant/abutment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brånemark implant/abutment assemblies
Trial: 11768928
Drug: Analgesics, tricyclic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Analgesics, tricyclic antidepressants, and other agents
Trial: 23690420
Drug: Tamoxifen plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamoxifen plus radiation therapy (TamRT)
Trial: 20953559
Drug: Topical quercetin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical quercetin applied two to three dabs three times daily
Trial: 20953559
Drug: Benzydamine hydrochloride
RxNorm normalized name: benzydamine hydrochloride
DrugBank: Benzydamine (DB09084)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benzydamine hydrochloride mouthwash used three times daily
Trial: 16884341
Drug: Massage therapy
RxNorm normalized name: CAMPHOR (SYNTHETIC) 30 g in 1 mL / MENTHOL 40 g in 1 mL TOPICAL OIL [CBDMEDIC MASSAGE THERAPY]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Massage therapy (twice weekly for 12 weeks)
Trial: 16884341
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (friendly visit, twice weekly for 12 weeks)
Trial: 8841224
Drug: One E2
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One E2 transdermal system
Trial: 8841224
Drug: Two E2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two E2 transdermal systems
Trial: 8841224
Drug: E2 transdermal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E2 transdermal system
Trial: 6383908
Drug: i.v. group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.v. group (insulin by continuous intravenous infusion)
Trial: 6383908
Drug: s.c. group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: s.c. group (conventional subcutaneous therapy)
Trial: 22466349
Drug: Progesterone (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Progesterone (200 mg twice daily for 5 weeks)
Trial: 22466349
Drug: Estradiol (100-μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estradiol (100-μg patch daily for 5 weeks)
Trial: 20227097
Drug: Retention sutured
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Retention sutured sequential fascial closure (RSSFC)
Trial: 18709009
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment (exposition, occlusive dressing, initial excision with skin grafting)
Trial: 15753413
Drug: IV immunoglobulin
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV immunoglobulin (IVIG) 0.4 g/kg body weight, administered at days 0, 1, 2, 30, and 60
Trial: 8971505
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no further oncologic treatment).
Trial: 27206648
Drug: Ibuprofen pretreatment
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ibuprofen pretreatment (800 mg) before catheterization (cohort 3)
Trial: 22126622
Drug: Oral health
RxNorm normalized name: CETYLPYRIDINIUM CHLORIDE 0.07 g in 100 mL ORAL RINSE [Assured Oral Health Fresh Mint]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral health education program targeting oral malodor prevention
Trial: 20123877
Drug: Extraoral infraorbital
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extraoral infraorbital nerve block (1.8 mL of 2% lidocaine with 1:100,000 epinephrine)
Trial: 20123877
Drug: Intraoral infraorbital
RxNorm normalized name: ALCOHOL 80 mL in 100 mL INTRADURAL LIQUID [80% Alcohol Hand Sanitizer]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraoral infraorbital nerve block (1.8 mL of 2% lidocaine with 1:100,000 epinephrine)
Trial: 12120905
Drug: Methotrexate once
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate once weekly
Trial: 12120905
Drug: Methotrexate twice
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate twice weekly
Trial: 12120905
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups (once weekly and twice weekly)
Trial: 10451039
Drug: Eprosartan 400
RxNorm normalized name: eprosartan 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eprosartan 400 mg total daily dose (b.i.d.), increased to 600 and 800 mg if necessary
Trial: 10451039
Drug: Enalapril 10
RxNorm normalized name: enalapril 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril 10 mg total daily dose (o.d.), increased to 20 and 40 mg if necessary
Trial: 21668768
Drug: Carbetocin (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbetocin (100 μg)
Trial: 28652463
Drug: Homeostasis model
RxNorm normalized name: CALCIUM HOMEOSTASIS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Homeostasis model of insulin resistance
Trial: 25872567
Drug: Daily oral
RxNorm normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily oral curcumin at the target dose determined in Phase I
Trial: 25872567
Drug: Standard care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard care oxaliplatin-based chemotherapy alone
Trial: 30642738
Drug: Oral citrulline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral citrulline supplementation
Trial: 29952809
Drug: Pulmonary Rehabilitation
RxNorm normalized name: Lobaria pulmonaria extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pulmonary Rehabilitation plus Oral Nutritional Supplement (PRONS) for 12 weeks
Trial: 15523452
Drug: Dextromethorphan (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dextromethorphan (1 mg/kg)
Trial: 16083921
Drug: Methylphenidate (Ritalin)
RxNorm normalized name: methylphenidate Oral Tablet [Ritalin]
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylphenidate (Ritalin) treatment
Trial: 12679222
Drug: S 18886
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S 18886 (10 mg single oral dose)
Trial: 3605567
Drug: Midazolam 0.15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam 0.15 mg/kg
Trial: 23144450
Drug: Pegloticase treatment
RxNorm normalized name: Pegloticase
DrugBank: Pegloticase (DB09208)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Pegloticase treatment
Trial: 24649935
Drug: 830 nm
RxNorm normalized name: NM-004
DrugBank: NM-004 (DB18066)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 830 nm low-level laser therapy (LLLT) administered five times per week for 2 weeks (average power 60 mW, peak power 8 W, 10 Hz, 600 sec, and 9.7 J/cm² per fracture site)
Trial: 24649935
Drug: Placebo group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo group received sham laser treatment
Trial: 22647618
Drug: PLP-dependent disturbances
RxNorm normalized name: PLP
DrugBank: Pyridoxal phosphate (DB00114)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PLP-dependent disturbances of tryptophan metabolism
Trial: 17852064
Drug: Stop Using
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stop Using Stuff (SUS) - a brief cognitive behavioural therapy (CBT) intervention, 4 to 6 sessions